about
Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patientsT-cell-mediated immunity and the role of TRAIL in sepsis-induced immunosuppressionInflammation in Chronic WoundsRefining anti-inflammatory therapy strategies for bronchopulmonary dysplasia.A peptide of heparin cofactor II inhibits endotoxin-mediated shock and invasive Pseudomonas aeruginosa infection.Impact of sepsis on CD4 T cell immunityAn updated meta-analysis to understand the variable efficacy of drotrecogin alfa (activated) in severe sepsis and septic shock.The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis.Lymph node fibroblastic reticular cell transplants show robust therapeutic efficacy in high-mortality murine sepsisRelease and activity of histone in diseases.Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysisDesign and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trialNear-infrared spectroscopy StO2 monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock.New insights for C5a and C5a receptors in sepsis.IMMUNE CELL PHENOTYPE AND FUNCTION IN SEPSIS.The role of extracellular histone in organ injury.Impact of thrombosis on pulmonary endothelial injury and repair following sepsis.Arterial thrombosis in the context of HCV-associated vascular disease can be prevented by protein C.Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition.The biology of natural killer cells during sepsis.Sepsis Associated Encephalopathy.
P2860
Q24202128-30B7C1D9-D85D-4F6E-8A9E-835E8C56E63EQ26823892-8C695AFA-E488-4A63-9243-91A412DD4AB1Q28075962-56B33A94-F5F6-4319-A374-0677B93DDF3FQ33684200-69FD2B40-371D-4F39-9291-68DCA40EBEA2Q33927961-7815B072-771B-48BB-A013-F86B35BB1D1AQ34341378-29749D23-FAE5-4DCA-9ED8-1D7F3D39FFADQ34486385-2782CD7F-9C4F-4EDE-9B0F-0DD78392C3D7Q35067228-7A03B176-B4ED-4BA3-A0C9-27A653EEB460Q35555569-EF49CCDB-9763-400F-B4A1-89CB184EF2ACQ35679542-FE0C5867-F1AD-4E79-A1A4-FB65F3EC0B25Q36715005-50F03620-B6D7-4571-B233-662E29483EB5Q36877358-34F05B66-200D-445B-8AD3-8D3F09EA6B73Q37356648-2730FAFD-4081-430A-85B1-D6A0CFC190B2Q38066943-C9844B91-E46E-4F75-972A-E5FD346BF805Q38412875-7DC853CC-E05A-4507-9B42-41FEA9E34678Q38679240-8763C702-D1EC-4655-ABEE-54869E56D930Q39107051-34E0100C-F83B-4472-AB3A-2D04BB01FA07Q40711044-1671675D-451A-4513-9E39-99100218E059Q47350943-AD009040-2BD0-4F69-AF18-BC68F02744BFQ47602497-12B4022D-CA8B-4F11-B1B7-BFE6EA73C88CQ54941463-22BDDBFC-71DC-4F93-906D-D51971831294
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Human recombinant activated protein C for severe sepsis
@ast
Human recombinant activated protein C for severe sepsis
@en
Human recombinant activated protein C for severe sepsis
@en-gb
Human recombinant activated protein C for severe sepsis
@nl
type
label
Human recombinant activated protein C for severe sepsis
@ast
Human recombinant activated protein C for severe sepsis
@en
Human recombinant activated protein C for severe sepsis
@en-gb
Human recombinant activated protein C for severe sepsis
@nl
prefLabel
Human recombinant activated protein C for severe sepsis
@ast
Human recombinant activated protein C for severe sepsis
@en
Human recombinant activated protein C for severe sepsis
@en-gb
Human recombinant activated protein C for severe sepsis
@nl
P2860
P50
P3181
P1476
Human recombinant activated protein C for severe sepsis
@en
P2093
Dimitrios Lathyris
P2860
P3181
P356
10.1002/14651858.CD004388.PUB5
P577
2012-03-14T00:00:00Z